Paroxetine: Clinical Overview
Indications
Paroxetine is FDA-approved for major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and post-traumatic stress disorder in adults 1. The controlled-release formulation additionally treats premenstrual dysphoric disorder 2. Off-label, it's used for chronic headache and vasomotor symptoms (7.5 mg dose for hot flashes is the only FDA-approved non-hormonal treatment for menopausal VMS) 3.
Dosing Regimen
Standard Dosing
- Major Depressive Disorder: Start 20 mg once daily, typically in the morning. May increase in 10 mg increments at intervals of at least 1 week. Maximum 50 mg/day 1.
- OCD: 40-60 mg/day is effective; 20 mg/day shows minimal benefit. Start at 20 mg and titrate to 40 mg 1.
- Panic Disorder: Target dose 40 mg/day (mean effective dose in trials). Start 10 mg and titrate upward 1.
- Social Anxiety Disorder: 20 mg/day is effective; higher doses (40-60 mg) show no additional benefit 1.
- GAD: 20-40 mg/day; no clear advantage for 40 mg over 20 mg 1.
- Vasomotor Symptoms: 7.5 mg at bedtime (lower than psychiatric doses, reducing side effects) 3.
Special Populations
- Elderly: Reduce initial dose due to 70-80% higher plasma concentrations. Start 10 mg/day 1.
- Severe renal impairment (CrCl <30 mL/min): Start 10 mg/day; plasma levels are 4-fold higher 1.
- Hepatic impairment: Start 10 mg/day; plasma levels are 2-fold higher 1.
- Moderate renal impairment (CrCl 30-60 mL/min): Start 10 mg/day; plasma levels are 2-fold higher 1.
Pharmacokinetic Considerations
- Half-life: 21 hours (supports once-daily dosing) 1.
- Steady state: Achieved in 4-14 days 4.
- Non-linear kinetics due to saturable CYP2D6 metabolism; doubling the dose more than doubles plasma levels 1.
- Therapeutic drug monitoring suggests optimal plasma concentration of 65-120 ng/mL for MDD; levels >120 ng/mL increase adverse effects without additional benefit 5.
Contraindications and Critical Warnings
Absolute Contraindications
- Concurrent use with MAO inhibitors or within 14 days of discontinuation 3.
- Concurrent use with thioridazine or pimozide (CYP2D6 interactions) 1.
Major Drug Interactions
- Tamoxifen: Paroxetine is a potent CYP2D6 inhibitor and significantly reduces conversion of tamoxifen to its active metabolite. Avoid paroxetine in patients on tamoxifen 3.
- CYP2D6 substrates: Inhibits metabolism of desipramine, risperidone, atomoxetine 1.
- Serotonergic drugs: Risk of serotonin syndrome with other SSRIs, SNRIs, triptans, tramadol 3.
FDA Safety Alerts
- Teratogenicity: Increased risk of cardiac malformations in first trimester 6.
- Persistent pulmonary hypertension of newborn: Risk with late pregnancy exposure 6.
- Suicidality: Increased risk in patients <25 years old 6.
- Discontinuation syndrome: Paroxetine has the highest risk among SSRIs due to short half-life and lack of active metabolites 2, 4.
Adverse Effects Profile
Common Side Effects (dose-dependent)
- Nausea, fatigue, dizziness 3
- Sedation and constipation (more than other SSRIs due to anticholinergic activity) 2
- Sexual dysfunction (higher rates than fluoxetine, sertraline, nefazodone, fluvoxamine) 7
- Weight gain (higher propensity than other SSRIs) 2
Serious Adverse Effects
- Liver injury and weight gain more common at plasma concentrations >120 ng/mL 5
- Serotonin syndrome with drug combinations 6, 3
Monitoring Recommendations
Initial Phase (Weeks 0-4)
- Assess tolerability at week 1-2 (nausea, sedation, dizziness)
- Monitor for activation/agitation, particularly in patients <25 years
- Consider therapeutic drug monitoring at week 4 if inadequate response; target 65-120 ng/mL 5
Maintenance Phase
- Assess response using standardized scales (HDRS, HAMA, YBOCS depending on indication)
- Monitor weight and metabolic parameters
- Screen for sexual dysfunction
- Liver function tests if high plasma concentrations suspected or clinical concern 5
Long-term Considerations
- Relapse prevention: Demonstrated efficacy for 1 year in MDD (15% vs 39% relapse on placebo), 6 months in panic disorder, and 6 months in OCD 1.
- Taper slowly when discontinuing to minimize withdrawal symptoms (more problematic than other SSRIs) 2.
Clinical Context from Guidelines
The 2023 ACP guideline recommends selecting between cognitive behavioral therapy or second-generation antidepressants (including paroxetine) for major depressive disorder after discussing adverse effects, cost, and patient preferences 8. The guideline notes paroxetine has higher sexual dysfunction rates than some alternatives 7. For treatment-resistant depression, switching from paroxetine to mirtazapine versus augmenting paroxetine with mirtazapine showed no difference in efficacy 8.
Key Pitfall
Do not prescribe paroxetine to patients taking tamoxifen for breast cancer - this is the most critical drug interaction that can compromise cancer treatment efficacy 3.